Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, +12

Journal of Thoracic Oncology

Kras MutationsMedicineReceptor Tyrosine KinasePathologyImportant Predictors +6

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Piero Ferollà, Maria Pia Brizzi, Tim Meyer, +19

The Lancet Oncology

Long-acting PasireotideOncologyMedicineClinical TrialsPathology +8

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Giulio Metro, Rita Chiari, Simona Duranti, +10

Lung Cancer

Clinical OutcomeSpecific Mutant KrasMedicinePathologyCancer Genomics +8

Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826).

Maria Grazia Ghi, Adriano Paccagnella, Daris Ferrari, +17

Journal of Clinical Oncology

Surgical OncologyInduction TpfPharmacotherapyOral CancerRadiation Medicine +14

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

Vienna Ludovini, Irene Floriani, Lorenza Pistola, +10

Journal of Thoracic Oncology

Cytidine DeaminaseOncogenic AgentMedicinePathologyBronchial Neoplasm +6

Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain

Vincenzo Minotti, L. Patoia, Fausto Roila, +5

Pain

The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy

Davide Tassinari, Luigi Montanari, Marco Maltoni, +10

Supportive Care in Cancer

Palliative CarePalliative Prognostic ScorePrognostic EvaluationMedicinePrognosis +5

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis

Rita Chiari, Giulio Metro, Daniela Iacono, +12

Lung Cancer

Multicenter AnalysisMedicinePathologyBronchial NeoplasmImmune Checkpoint Inhibitor +7

Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non–Small-Cell Lung Cancer Segregated According to KRAS Mutation Status

Giulio Metro, Rita Chiari, Chiara Bennati, +11

Clinical Lung Cancer

MedicinePathologyMolecular OncologyKras Mutation StatusCancer Treatment +7

Long-Term Response to Gefitinib and Crizotinib in Lung Adenocarcinoma Harboring Both Epidermal Growth Factor Receptor Mutation and <i>EML4-ALK</i> Fusion Gene

Rita Chiari, Simona Duranti, Vienna Ludovini, +5

Journal of Clinical Oncology

Tumor BiologyMedicineCancer GrowthCancer Cell BiologyEpithelial-mesenchymal Interactions +9